Ziltivekimab

Highest phase reached

Phase 3

www.ebi.ac.uk

Drug type

Antibody

www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Phase 3
www.ebi.ac.uk

Drug type: Antibody
www.ebi.ac.uk

Drug name: Ziltivekimab
www.ebi.ac.uk

cor 001
Cor-001
COR-001
cor001
COR001
Immunoglobulin G1 [255-tyrosine,257-threonine,259-glutamic acid], anti-(human interleukin 6) (human monoclonal 2E2.3A9.6A3 γ1-chain), disulfide with human monoclonal 2E2.3A9.6A3 κ-chain, dimer
immunoglobulin g1 255 tyrosine 257 threonine 259 glutamic acid anti human interleukin 6 human monoclonal 2e2 3a9 6a3 γ1 chain disulfide with human monoclonal 2e2 3a9 6a3 κ chain dimer
immunoglobulin g1 kappa anti homo sapiens il6 interleukin 6 il 6 monoclonal antibody gamma1 heavy chain humanized 1 450 vh homo sapiens ighv3 66 01 88 8 ighd ighj1 01 90 9 8 8 13 1 120 homo sapiens ighg1 03 g1m3 ng1m1 ch1 r120 217 121 218 hinge 1 15 219 233 ch2 m15 1 y 255 s16 t 257 t18 e 259 234 343 ch3 e12 359 m14 361 344 448 chs 449 450 121 450 223 213 disulfide with kappa light chain homo sapiens 1 213 v kappa homo sapiens igkv1 5 03 96 7 igkj2 03 100 6 3 8 1 106 homo sapiens igkc 01 100 km3 a45 1 152 v101 190 107 213 dimer 229 229 232 232 bisdisulfide produced in chinese hamster ovary cho gs cell line glycoform alfa
immunoglobulin G1-kappa, anti-[Homo sapiens IL6 (interleukin 6, IL-6)], monoclonal antibody; gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (88.8%) -(IGHD) -IGHJ1*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03 G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 M15.1>Y (255), S16>T (257), T18>E (259) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-213')-disulfide with kappa light chain Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-5*03 (96.7%) -IGKJ2*03 (100%)) [6.3.8] (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-GS cell line, glycoform alfa
medi 5117
Medi 5117
MEDI 5117 [WHO-DD]
medi 5117 who dd
Medi-5117
MEDI-5117
medi5117
MEDI5117
nn 6018
NN-6018
nn6018
NN6018
wbp 216
WBP-216
wbp216
WBP216

And 8 more, listed on the interactive page.

CAS registry numbers

2226654-05-1

ChEMBL ID: CHEMBL4297732
www.ebi.ac.uk

FDA ingredient codes (UNII)

AN3Y2B4SX4

First in class: No
Orphan designation: No

Pharmacology name: ziltivekimab
Type: Antibody
Drug name stem: -mab

Mechanism
Interleukin-6 binding agent
Action type
BINDING_AGENT
Target
Interleukin-6
Protein identifier
P05231
Action
Binding
Action type
Binding
Target
IL-6
Gene symbol
IL-6
Median affinity
11
Affinity units
pKd
Action
Binding
Action type
Binding
Target
Fc fragment of IgG receptor and transporter
Gene symbol
FCGRT
Protein identifier
P55899
Median affinity
6.65
Affinity units
pKd
Mechanism
Interleukin-6 inhibitor
Action type
Inhibitor
Target
Interleukin-6
Protein identifier
P05231

Mechanism
Interleukin-6 binding agent
Action type
BINDING AGENT
Target
Interleukin-6
Mechanism
Interleukin-6 inhibitor
Action type
Inhibitor
Target
Interleukin-6

Condition
Arthritis, Rheumatoid
Highest recorded phase
1
Condition identifier
EFO:0000685
Subject identifier
D001172
Condition
Renal Insufficiency, Chronic
Highest recorded phase
1
Condition identifier
EFO:0003884
Subject identifier
D051436
Condition
Heart Disease Risk Factors
Highest recorded phase
1
Condition identifier
EFO:0004252
Subject identifier
D000082742
Condition
Anemia
Highest recorded phase
1
Condition identifier
EFO:0004272
Subject identifier
D000740

Condition identifier
EFO_0000319
Highest recorded phase
1
Condition identifier
EFO_0000685
Highest recorded phase
1
Condition identifier
EFO_0003144
Highest recorded phase
3
Condition identifier
EFO_0003884
Highest recorded phase
1
Condition identifier
EFO_0004252
Condition identifier
EFO_0004272
Condition identifier
EFO_0004272
Highest recorded phase
1
Condition identifier
MONDO_0004781
Highest recorded phase
3
Condition identifier
MONDO_0004995
Highest recorded phase
1
Condition identifier
MONDO_0005010
Highest recorded phase
3
Condition identifier
MONDO_0005252
Highest recorded phase
3
Condition identifier
MONDO_0005300
Highest recorded phase
2
Condition identifier
MONDO_0005311
Highest recorded phase
3
Condition identifier
MONDO_0005375
Condition identifier
MONDO_0008383
Highest recorded phase
1
Condition identifier
MONDO_0021661
Highest recorded phase
3
Condition identifier
MP_0001845
Highest recorded phase
1

NCT01559103
clinicaltrials.gov
NCT02868229
clinicaltrials.gov
NCT03126318
clinicaltrials.gov

Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Natural product: No

Component
Heavy chain
Type
Protein
Sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Component
Disulfide bridges
Sequence
22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 133'-193' $ 133'''-193''' $ 147-203 $ 147''-203'' $ 223-213' $ 223''-213''' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''
Component
Light chain
Type
Protein
Sequence
DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Component
Glycosylation sites (N)
Sequence
300 $ 300''

Related records

Trials (14)

A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Specifying the Anti-inflammatory Effects of Ziltivekimab
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

In development for (6)

Targets (1)

IL6 Interleukin-6 binding agent; Interleukin-6 inhibitor

Ziltivekimab

Development status

Names and chemistry

Other names (33)

Identifiers

Regulatory information

Other regulatory facts

Pharmacology

Drug classification

Mechanisms of action (4)

Open Targets mechanisms (2)

Investigated indications (4)

Open Targets indications (17)

Trial references (3)

Chemical properties

Sequences (4)

Related records

Trials (14)

In development for (6)

Targets (1)